YU71393A - Preparati za regulaciju dejstva citokina - Google Patents

Preparati za regulaciju dejstva citokina

Info

Publication number
YU71393A
YU71393A YU71393A YU71393A YU71393A YU 71393 A YU71393 A YU 71393A YU 71393 A YU71393 A YU 71393A YU 71393 A YU71393 A YU 71393A YU 71393 A YU71393 A YU 71393A
Authority
YU
Yugoslavia
Prior art keywords
host
sulfated
acetylated
substances
substantially purified
Prior art date
Application number
YU71393A
Other languages
English (en)
Inventor
R.I. Cohen
Lider Ofer
Cahalon Liora
Shoseyou Odeo
Margalit Raanan
Original Assignee
Veda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veda Research And Development Co. Ltd. filed Critical Veda Research And Development Co. Ltd.
Publication of YU71393A publication Critical patent/YU71393A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Saccharide Compounds (AREA)

Abstract

Pronalazak se odnosi na supstance koje sadrže karboksilovane i/ili sulfatisane oligosaharide, u suštinski čistom obliku, formule (I) u kojoj X1 je vodonik ill sulfat; X2 je vodonik ili sulfat; X3 je sulfat ili acetil, kao i na preparate koji ih sadrže i na postupke koji ih koriste u cilju regulacije aktivnosti citokina u domaćinu. Tako, na primer, sekrecija faktora tumorske nekroze alfa (TNF-alfa) može se selektivno inhibirati ili pojačati, davanjem domaćinu delotvornih količina supstanci, ili njihovih preparata, koje sadrže specifične oligosaharide u, suštinski, čistom obliku. Prema tome, prikazani pronalazak se takođe odnosi i na farmaceutske preparate i na njihovu upotrebu za sprečavanje i/ili lečenje patoloških procesa koji uključuju indukciju sekrecije aktivnih citokina, kao što je TNF-alfa. Pronalazak se takodje odnosi na iniciranje u domaćinu željenog imunskog odgovora na prisustvo aktivatora, uključujući patogene. Supstance i preparati prema prikazanom pronalasku mogu se davati dnevno, u vrlo malim efektivnim dozama, tipično ispod 0,1 mg/kg čoveka, ili u intervalima od oko 5-8 dana, poželjno jednom nedeljno.
YU71393A 1992-11-10 1993-11-10 Preparati za regulaciju dejstva citokina YU71393A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97475092A 1992-11-10 1992-11-10
US9673993A 1993-07-23 1993-07-23

Publications (1)

Publication Number Publication Date
YU71393A true YU71393A (sh) 1997-05-28

Family

ID=26792027

Family Applications (1)

Application Number Title Priority Date Filing Date
YU71393A YU71393A (sh) 1992-11-10 1993-11-10 Preparati za regulaciju dejstva citokina

Country Status (18)

Country Link
EP (2) EP1095657B1 (sh)
JP (1) JPH08506322A (sh)
CN (1) CN1093904A (sh)
AT (1) ATE201327T1 (sh)
AU (2) AU686581B2 (sh)
CA (1) CA2149116A1 (sh)
DE (2) DE69330252T2 (sh)
FI (1) FI952267A (sh)
HR (1) HRP931389A2 (sh)
HU (1) HUT70945A (sh)
IL (1) IL107563A (sh)
NO (1) NO951822L (sh)
NZ (1) NZ258367A (sh)
PL (1) PL309001A1 (sh)
SI (1) SI9300586A (sh)
TW (1) TW257678B (sh)
WO (1) WO1994011006A1 (sh)
YU (1) YU71393A (sh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750207B1 (en) 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
WO1994011006A1 (en) * 1992-11-10 1994-05-26 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
AU2002243630A1 (en) 2001-01-23 2002-08-06 Massachusetts Institute Of Technology Solid- and solution -phase synthesis of heparin and other glycosaminoglycans
US7285536B2 (en) 2001-12-05 2007-10-23 Yeda Research And Development Co., Ltd. Anti-cancer therapeutic compounds
ITMI20021294A1 (it) * 2002-06-12 2003-12-12 Inalco Spa Polisaccaridi batterici o-solfatati e loro uso
US20060293275A1 (en) * 2004-03-29 2006-12-28 Toshikazu Nakamura Hgf production accelerator containing heparin-like oligosaccharide
ITMI20091445A1 (it) * 2009-08-07 2011-02-08 Inalco S P A A Socio Unico Derivati semi-sintetici del polisaccaride k5 per la prevenzione ed il trattamento del danno tissutale associato a ischemia e/o riperfusione
US8992653B2 (en) 2011-09-08 2015-03-31 Novozymes Bioag A/S Seed treatment methods and compositions
MX351416B (es) * 2011-09-23 2017-10-13 Novozymes Bioag As Quitooligosacaridos y metodos para el uso en el mejoramiento de crecimiento de plantas.
CN102824352B (zh) * 2011-10-11 2013-09-04 泸州医学院 一种双糖化合物在制备抗肿瘤药物中的用途
CN109730006B (zh) * 2019-03-19 2022-10-18 西华大学 提高动物黑色素含量的方法
CN110646557A (zh) * 2019-10-12 2020-01-03 北京航空航天大学 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途
EP4117683A4 (en) 2020-03-12 2024-04-24 Cullis Hill Sydney David TREATMENT OF CORONAVIRUS INFECTION AND ASSOCIATED CYTOKINE TOXICITY

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4818816A (en) * 1981-04-28 1989-04-04 Choay, S.A. Process for the organic synthesis of oligosaccharides and derivatives thereof
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides
FR2538404B1 (sh) * 1982-12-28 1985-08-23 Anic Spa
IT1195497B (it) * 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
FR2597484B1 (fr) * 1986-04-17 1988-12-23 Sanofi Sa Glycosaminoglycanes de type heparine ou heparane-sulfate dotes d'une activite sur la division et la differentiation cellulaires, leur preparation et leurs applications therapeutiques.
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
JPH0818993B2 (ja) * 1989-11-28 1996-02-28 キッセイ薬品工業株式会社 プロスタグランジンｉ▲下２▼産生増強剤
BE1004029A6 (nl) * 1990-11-22 1992-09-08 Mol Omer De Farmaceutische samenstelling en farmaceutische set voor het behandelen van kanker.
DE69232615T2 (de) * 1991-05-02 2003-01-30 Yeda Res & Dev Zusammensetzungen zur verhütung und/oder behandlung von pathologischen prozessen
WO1994011006A1 (en) * 1992-11-10 1994-05-26 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity

Also Published As

Publication number Publication date
EP1095657A2 (en) 2001-05-02
EP1095657A3 (en) 2004-02-25
DE69334102T2 (de) 2007-10-18
HU9501373D0 (en) 1995-06-28
AU686581B2 (en) 1998-02-12
NO951822L (no) 1995-06-29
SI9300586A (en) 1994-09-30
IL107563A (en) 2006-12-31
PL309001A1 (en) 1995-09-18
CA2149116A1 (en) 1994-05-26
HUT70945A (en) 1995-11-28
DE69330252D1 (de) 2001-06-28
EP0669827A1 (en) 1995-09-06
EP0669827A4 (en) 1996-08-28
DE69334102D1 (de) 2007-02-22
CN1093904A (zh) 1994-10-26
EP0669827B1 (en) 2001-05-23
HRP931389A2 (en) 1995-04-30
FI952267A (fi) 1995-07-10
ATE201327T1 (de) 2001-06-15
NZ258367A (en) 1997-02-24
NO951822D0 (no) 1995-05-09
AU5599394A (en) 1994-06-08
FI952267A0 (fi) 1995-05-10
AU6478398A (en) 1998-06-25
IL107563A0 (en) 1994-02-27
DE69330252T2 (de) 2002-02-07
EP1095657B1 (en) 2007-01-10
JPH08506322A (ja) 1996-07-09
TW257678B (sh) 1995-09-21
AU699624B2 (en) 1998-12-10
WO1994011006A1 (en) 1994-05-26

Similar Documents

Publication Publication Date Title
YU71393A (sh) Preparati za regulaciju dejstva citokina
CA2118121C (en) Methods and compositions for the treatment of diseases with interferon while reducing side effects
EP0625991A4 (en) IMPROVED ALPHA INTERFERON COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF FROM LEUKOCYTES OF THE HUMAN PERIPHERAL BLOOD.
NZ251320A (en) Bis-aromatic alpha,beta-unsaturated ketones, preparation and use in pharmaceutical compositions
SG49625A1 (en) Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
DE69636308D1 (de) Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
AU4319493A (en) Indolocarbazole imides and their use
HUT67436A (en) Process to prepare novel hydroxamic acid and n-hydroxyurea derivatives and pharmaceutical compn.s contg. them
Shalit Immunological aspects of new quinolones
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
Morahan et al. Antimicrobial activity of various immunomodulators: independence from normal levels of circulating monocytes and natural killer cells
DE59108104D1 (de) Arzneimittel enthaltend cd14
OA09665A (fr) Esters d'aminoacides de l'hydroquinone, leur procédé de préparation et compositions pharmaceutiques ou cosmétiques les contenant
Zicari et al. Stimulation of macrophages with IFNγ or TNFα shuts off the suppressive effect played by PGE2
RU95113594A (ru) Композиции для регулирования активности цитокина
Dupuy Natural resistance against mouse hepatitis virus 3
Serrou et al. In vitro and in vivo modulation of the immune response by human fibroblast interferon (HFI)
Ehel'ben Our experience in the treatment of thermal burns
MASAOKA CANCER CHEMOTHERAPY AND G-CSF
WO1994008474A3 (en) Medical food and method of administration
KR19990013196A (ko) 신규 항암제 조성물